Navigation Links
Global Orphan Drug Market Future Outlook 2015-2020
Date:6/8/2015

DUBLIN, June 08, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/g8q842/global_orphan) has announced the addition of the "Global Orphan Drug Market Future Outlook 2020" report to their offering.

In recent years, several new rare diseases are being included in clinical trials for the development of orphan drug candidate. Oncology, Genetic diseases, Autoimmune, pulmonary disease, Central nervous system and others are main focus of orphan drug developers. All of these diseases have large patient base but their rare forms doesn't have suitable therapeutics which reflects the marketing potential of orphan drugs in these segments.

Out of these, oncology segment has got maximum attention followed by rare genetic disorders, neurological disorder and autoimmune disorders. In a bigger view, orphan drug segment is expected to grow several folds in coming years due to several favorable factors. Introduction of innovative technologies, favorable pricing, reimbursement, unmet medical necessities and strong clinical pipeline could be attributed as important factors responsible for their growth.

"Global Orphan Drug Market Future Outlook 2020" report highlights:

- Global Orphan Drug Market Overview
- Global Orphan Drug Market Segment Analysis
- FDA & EMA Regulation for Clinical Trials Orphan Designated Drugs
- Orphan Drug Designation Criteria & Reimbursement Policy by Region
- Comprehensive Insight on Global Orphan Drugs Clinical Pipeline & Patent Analysis by Company, Country, Indication & Phase
- Global Orphan Drugs Clinical Pipeline: 697 Drugs
- Majority Orphan Drugs in Phase-II Trials: 249 Drugs
- Marketed Orphan Drugs: 274 Drugs

Key Topics Covered:

1. Introduction to Orphan Drug

2. Favorable Market Dynamics for Orphan Drugs Commercialization

3. Global Orphan Drug Market Overview

4. Global Orphan Drug Market Segment Analysis

5. Global Orphan Drug Clinical Pipeline Overview

6. US Orphan Drug Market Overview

7. Europe Orphan Drug Market Overview

8. Asia Orphan Drug Market Overview

9. FDA Regulation for Clinical Trials Orphan Designated Drugs

10. EMA Regulations for Clinical Trials of Orphan Designated Drugs

11. Asian Regulations for Clinical Trials of Orphan Designated Drugs

12. Global Orphan Drugs Clinical Pipeline Insight & Patent Analysis by Company, Country, Indication & Phase

13. Marketed Orphan Drugs Clinical Insight & Patent Analysis by Company, Country & Indication

14. Discontinued & Suspended Orphan Drugs in Clinical Trials

15. Competitive Landscape

- AOP Orphan
- Agenus
- Alexion
- Biogen Idec
- Bristol Myers Squibb
- Celgene
- Eli Lilly
- Genethon
- Genzyme Corporation
- Glaxosmithkline
- Merck
- Novartis Pharmaceuticals
- Orphan Europe
- Pfizer
- Prosensa
- Rare Disease Therapeutics
- Roche
- Sanofi
- Shire
- Teva Pharmaceutical

For more information visit http://www.researchandmarkets.com/research/g8q842/global_orphan

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net


'/>"/>
SOURCE Research and Markets
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Streptavidin (CAS 9013-20-1): Market Research Report 2015
2. AbbVie to Present at Goldman Sachs 36th Annual Global Healthcare Conference
3. Global Healthcare Financial Analytics Market 2015 - Growth, Trends & Forecast To 2020
4. Quest Diagnostics to Speak at the Goldman Sachs 36th Annual Global Healthcare Conference
5. Isis Pharmaceuticals to Present at the Goldman Sachs 36th Annual Global Healthcare Conference
6. Global Halogen Surgical Light Industry Report 2015
7. Global Electric Surgical Liposuction Pump Industry Report 2015
8. Global Surgical Incision Closures Industry
9. Global Blood Processing Supplies and Equipment Industry
10. Elastomers: Applications and Global Markets
11. Global Laboratory Centrifuges Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... 28, 2017 Cohen Veterans Bioscience and Early ... of wearable and home sensors for real-time monitoring of ... Foundation, a nonprofit organization focused on disruptive health solutions ... affordable analytical system to record and integrate behavioral, cognitive, ... ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017 ... , and OptiMed Specialty Pharmacy of Kalamazoo, ... offer a strategic hub service that expedites and streamlines ... personal spirometer, Spiro PD 2.0, and wellness management services.  ... is a medical device used to measure lung function ...
Breaking Medicine Technology:
(Date:10/13/2017)... LEXINGTON, Ky. (PRWEB) , ... October 13, 2017 , ... ... MD, MPH to become its next President and Chief Executive Officer, succeeding Dr. James ... and CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder ... of ElderCounsel, a national organization of elder law and special needs planning attorneys. “Membership ... rules. It also provides a forum to network with elder law attorneys nationwide,” said ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
Breaking Medicine News(10 mins):